clinical trial · NCT05287126
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Ulcerative ColitisEtrasimod
brief summary
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to \< 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment).
started
Dec 16, 2022
primary completion
Jun 16, 2029
completion
Jul 10, 2033
last updated
May 15, 2026
official title
An Open-Label, Single-Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol